Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer ; volume:26 ; number:1 ; day:7 ; month:2 ; year:2024 ; pages:1-13 ; date:12.2024
Breast cancer research ; 26, Heft 1 (7.2.2024), 1-13, 12.2024
- Creator
-
Rönnlund, Caroline
Sifakis, Emmanouil G.
Schagerholm, Caroline
Yang, Qiao
Karlsson, Emelie
Chen, Xinsong
Foukakis, Theodoros
Weidler, Jodi
Bates, Michael
Fredriksson, Irma
Robertson, Stephanie
Hartman, Johan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-024-01779-9
- URN
-
urn:nbn:de:101:1-2404160807549.984575573983
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rönnlund, Caroline
- Sifakis, Emmanouil G.
- Schagerholm, Caroline
- Yang, Qiao
- Karlsson, Emelie
- Chen, Xinsong
- Foukakis, Theodoros
- Weidler, Jodi
- Bates, Michael
- Fredriksson, Irma
- Robertson, Stephanie
- Hartman, Johan
- SpringerLink (Online service)
Other Objects (12)
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients